COST-EFFECTIVENESS ANALYSIS OF OBINUTUZUMAB/CHLORAMBUCIL VS RITUXIMAB/CHLORAMBUCIL IN TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
Author(s)
Yagudina R, Kulikov A, Babiy VV
I.M. Sechenov First Moscow State Medical University, Moscow, Russia
OBJECTIVES: To conduct a cost-effectiveness assessment of obinutuzumab/chlorambucil (G-Clb) vs rituximab/chlorambucil (R-Clb) in treatment of chronic lymphocytic leukemia (1st line treatment) among elderly patients with coexisting conditions in the Russian Federation. METHODS: To conduct present study there was developed a special model (time horizon – 36 months). All necessary data was obtained from CLL 11. Effectiveness analysis was based on the following criteria – number of life years. Cost analysis included only direct costs on the treatment of CLL (1st line: G-Clb or R-Clb, 2nd and 3rd lines – Bendamustin-Rituximab) and severe adverse events. Cost data was based on median prices for medicines and medical services in National healthcare system in the Russian Federation. RESULTS: Total costs per patient in the group of G-Clb were 3217189 rubbles (€ 59688) and for R-Clb - 3102020 rubbles (€ 57552). The number of life years for G-Clb was 2,88 and for R-Clb - 2,75. Cost-effectiveness ratio for G-Clb was 1116724 (€ 20719) and for R-Clb was 1129204 rubbles (€ 20950). CONCLUSIONS: Due to the lower cost-effectiveness ratio, the use of G-Clb instead of R-Clb in treatment of CLL among elderly patients with coexisting conditions in the Russian Federation is more reasonable from a pharmacoeconomic point of view
Conference/Value in Health Info
2015-11, ISPOR Europe 2015, Milan, Italy
Value in Health, Vol. 18, No. 7 (November 2015)
Code
PCN169
Topic
Economic Evaluation
Topic Subcategory
Cost-comparison, Effectiveness, Utility, Benefit Analysis
Disease
Oncology